Skip to main content

Clinical significance of genetic influences on cardiovascular drug metabolism

Cardiovascular Drugs and Therapy volume 7, pages 311–324 (1993)Cite this article

Summary

Inherited differences in metabolism may be responsible for individual variability in the efficacy of drugs and the occurrence of adverse drug reactions. Among the cardiovascular drugs reported to exhibit genetic polymorphism are debrisoquine, sparteine, some beta-adrenoceptor antagonists, flecainide, encainide, propafenone, nifedipine, procainamide, and hydralazine. The implications of genetic differences in the metabolism of these drugs for cardiovascular therapeutics is the subject of this review.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Eichelbaum M, Spannrucker N, Steincke B, et al. Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.Eur J Clin Pharmacol 1979;16:183–187.

    PubMed  Google Scholar 

  2. Mahgoub A, Idle J, Dring L, et al. Polymorphic hydroxylation of debrisoquine in man.Lancet 1977;2:584–586.

    PubMed  Google Scholar 

  3. Eichelbaum M, Gross A. The genetic polymorphism of debrisoquine/sparteine metabolism—clinical aspects.Pharmacol Ther 1990;46:377–394.

    PubMed  Google Scholar 

  4. Nebert D, Gonzalez F. P450 genes. Their structure, evolution and regulation.Ann Rev Biochem 1987;56:945–993.

    PubMed  Google Scholar 

  5. Eichelbaum M, Bertilsson L, Sawe J. Polymorphic oxidation of sparteine and debrisoquine: related pharmacogenetic entities.Clin Pharmacol Ther 1982;31:184–186.

    PubMed  Google Scholar 

  6. Schmid B, Bircher J, Preisig R, et al. Polymorphic dextromethorphan metabolism: cosegregation of oxidative O-demethylation with debrisoquin hydroxylation.Clin Pharmacol Ther 1985;38:618–624.

    PubMed  Google Scholar 

  7. Hou Z, Pickle L, Meyer P, et al. Salivary analysis for determination of dextromethorphan metabolic phenotype.Clin Pharmacol Ther 1991;49:410–419.

    PubMed  Google Scholar 

  8. Steiner E, Bertilsson L, Sawe J, et al. Polymorphic debrisoquine hydroxylation in 757 Swedish subjects.Clin Pharmacol Ther 1988;44;431–435.

    PubMed  Google Scholar 

  9. Kupfer A, Preisig R. Pharmacogenetics of mephenytoin: a drug hydroxilation polymorphism in man.Eur J Clin Pharmacol 1984;26:753–759.

    PubMed  Google Scholar 

  10. Kleinbloesem C, van Brummelen P, Faber H, et al. Variability in nifedipine pharmacokinetics and dynamics: new oxidation polymorphism in man.Biochem Pharmacol 1984;33:3721–3724.

    PubMed  Google Scholar 

  11. Sloan T, Lancaster R, Shah R. Genetically determined oxidation capacity and the disposition of debrisoquine.Br J Clin Pharmacol 1983;15:443–450.

    PubMed  Google Scholar 

  12. Jacqz E, Hall D, Branch R. Genetically determined polymorphisms in drug oxidation.Hepatology 1986;6:1020–1032.

    PubMed  Google Scholar 

  13. Leeman T, Dayer P, Meyer U. Single dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers.Eur J Clin Pharmacol 1986;29:739–741.

    PubMed  Google Scholar 

  14. Du Souich P, Erill S. Patterns of acetylation of procainamide and procainamide-derived p-aminobenzoic acid in man.Eur J Clin Pharmacol 1976;10:283–287.

    Google Scholar 

  15. Nebert D, Weber W. Pharmacogenetics. In:Principles of Drug Action 1990:399–530.

  16. Lennard M, Tucker G, Silas J, et al. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquine metabolizers.Clin Pharmacol Ther 1983;34:732–737.

    PubMed  Google Scholar 

  17. McGourty J, Silas J, Fleming J, et al. Pharmacokinetics and beta-blocking effects of timolol in poor and extensive metabolizers of debrisoquin.Clin Pharmacol Ther 1985;38:409–413.

    PubMed  Google Scholar 

  18. Alvan G, Von Bahr C, Seideman P, et al. High plasma concentrations of beta-receptor blocking drugs and deficient debrisoquine hydroxylation.Lancet 1982;1:333.

    Google Scholar 

  19. Dayer P, Leemann T, Kupfer A, et al. Stereo- and regio-selectivity of hepatic oxidation in man—effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation.Eur J Clin Pharmacol 1986;31:313–318.

    PubMed  Google Scholar 

  20. Lewis R, Lennard M, Jackson P, et al. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics.Br J Clin Pharmacol 1985;19:329–333.

    PubMed  Google Scholar 

  21. Formgren H. The effects of metoprolol and practolol on lung function and blood pressure in hypertensive asthmatics.Br J Clin Pharmacol 1976;3:1007–1014.

    Google Scholar 

  22. Greenblatt D, Koch-Weser J. Adverse reactions to beta-adrenergic receptor blocking drugs: a report from the Boston Collaborative Surveillance Program.Drugs 1974;7:118–129.

    PubMed  Google Scholar 

  23. Betts T, Alford C. Beta-blocking drugs and sleep. A controlled trial.Drugs 1983;25(Suppl 2):268–272.

    Google Scholar 

  24. Lennard M, Silas J, Freestone S, et al. Oxidation phenotype—A major determinant of metoprolol metabolism and response.N Engl J Med 1982:307:1558–1560.

    PubMed  Google Scholar 

  25. Silas J, Lennard G, Tucker L, et al. Polymorphic metabolism of beta-adrenoceptor antagonists.Br J Clin Pharmacol 1984;17:11S-19S.

    PubMed  Google Scholar 

  26. Wagner F, Jahnchen E, Trenk D, et al. Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine.Klin Wochenschr 1987;65:1164–1168.

    PubMed  Google Scholar 

  27. Wagner F, Kalusche D, Trenk D, et al. Drug interaction between propafenone and metoprolol.Br J Clin Pharmacol 1987;24:213–220.

    PubMed  Google Scholar 

  28. Bobik A, Jennings G, Ashley P, et al. Timolol pharmacokinetics and effects on heart rate and blood pressure after acute and chronic administration.Eur J Clin Pharmacol 1979;16:243–249.

    Google Scholar 

  29. Ferguson R, Vlasses P, Koplin J, et al. Relationships among timolol doses, plasma concentrations and beta-adrenoceptor blocking activity.Br J Clin Pharmacol 1982;14:719–725.

    PubMed  Google Scholar 

  30. Dayer P, Kuble A, Kupfer A, et al. Defensive hydroxylation of bufuralol associated with side effects of the drug in poor metabolisers.Br J Clin Pharmacol 1982;13:750–752.

    PubMed  Google Scholar 

  31. Dayer P, Courvoisier F, Balant L, et al. Beta-blocker and drug oxidation status.Lancet 1982;1:509.

    PubMed  Google Scholar 

  32. Walle T, Byington R, Furberg C, et al. Biological determinants of propranolol disposition: results from 1308 patients in the beta-blocker heart attack trial.Clin Pharmacol Ther 1985;38:509–518.

    PubMed  Google Scholar 

  33. Riddell J, Harron D, Shanks R. Clinical pharmacokinetics of beta-adrenoceptor antagonists: an update.Clin Pharmacokinet 1987;12:305–320.

    PubMed  Google Scholar 

  34. Vestal R, Wood A, Shand D. Reduced beta-adrenoceptor sensitivity in the elderly.Clin Pharmacol Ther 1979;26:181–186.

    PubMed  Google Scholar 

  35. Walle T, Walle U, Olanoff L. Quantitative account of propranolol metabolism in urine of normal man.Drug Metab Dispos 1985;13:204–205.

    PubMed  Google Scholar 

  36. Lennard M, Jackson P, Freestone S, et al. The relationship between debrisoquine oxidation phenotype and the pharmacokinetics and pharmacodynamics of propranolol.Br J Clin Pharmacol 1984;17:670–685.

    Google Scholar 

  37. Raghuram T, Koshakji R, Wilkinson G, et al. Polymorphic ability to metabolize propranolol alters 4-hydroxypropranolol levels, but not beta blockade.Clin Pharmacol Ther 1984;36:51–56.

    PubMed  Google Scholar 

  38. Schneck D, Pritchard J, Gibson T, et al. Effect of dose and uremia on plasma and urine profiles of propranolol metabolites.Clin Pharmacol Ther 1980;27:744–755.

    PubMed  Google Scholar 

  39. Silber B, Holford N, Riegelman S. Dose-dependent elimination of propranolol and its major metabolites in humans.J Pharm Sci 1983;72:725–732.

    PubMed  Google Scholar 

  40. Walle U, Walle T, Bai S, et al. Stereoselective binding of propranolol to human plasma, al-acid glycoprotein, and albumin.Clin Pharmacol Ther 1984;34;718–723.

    Google Scholar 

  41. Ward S, Walle T, Walle K, et al. Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities.Clin Pharmacol Ther 1989;45:72–79.

    PubMed  Google Scholar 

  42. Zhou-Hong-Hao, Koshaji R, Silberstein D, et al. Racial differences in drug response.N Engl J Med 1989;320-565–570.

    PubMed  Google Scholar 

  43. Shah R, Oates N, Idle J, et al. Beta-blockers and drug oxidation status.Lancet 1982;1:508–509.

    Google Scholar 

  44. Woosley A, Roden D, Duff H, et al. Co-inheritance of deficient oxidative metabolism of encainide and debrisoquine.Clin Res 1981;29:501A.

    Google Scholar 

  45. Woolsey A, Roden D, Dai G, et al. Co-inheritance of the polymorphic metabolism of encainide and debrisoquin.Clin Pharmacol Ther 1986;39;282–287.

    PubMed  Google Scholar 

  46. Wang D, Roden H, Wolfenden R, et al. Influence of genetic polymorphism on the metabolism and disposition of encainide in man.J Pharmacol Exp Ther 1984;228:605–611.

    PubMed  Google Scholar 

  47. Carey E, Duff H, Roden D. Encainide and its metabolites; comparative effects in man in ventricular arrhythmia and electrocardiographic intervals.J Clin Invest 1984;73:539–547.

    PubMed  Google Scholar 

  48. Roden D, Reele S, Aiggins S, et al. Total suppression of ventricular arrhythmias by encainide.N Engl J Med 1980;302:877–882.

    PubMed  Google Scholar 

  49. Bergstrand R, Wang T, Roden D, et al. Encainide disposition in patients with renal failure.Clin Pharmacol Ther 1986;40:64–70.

    PubMed  Google Scholar 

  50. Quart B, Durker J, Soyka L. Polymorphic encainide oxidation: what is the clinical significance?Acta Pharmacol Toxicol 1986;59 (Suppl V):116 (abstract 333).

    Google Scholar 

  51. Salerno D, Granrud G, Sharkey P, et al. Pharmacodynamics and side effects of flecainide acetate.Clin Pharmacol Ther 1986;40:101–107.

    PubMed  Google Scholar 

  52. Conard G, Ober R. Metabolism of flecainide.Am J Cardiol 1984;53:41B-51B.

    Article  PubMed  Google Scholar 

  53. McQuinn R, Quarforth G, Johnson J, et al. Biotransformation and elimination of C-flecainide acetate in humans.Drug Metab Dispos 1984;12;414–420.

    PubMed  Google Scholar 

  54. Forland S, Burgess E, Blair A, et al. Oral flecainide pharmacokinetics in patients with impaired renal function.J Clin Pharmacol 1988;28:259–267.

    PubMed  Google Scholar 

  55. Cavalli A, Maggioni A, March S, et al. Flecainide half-life prolongation in 2 patients with congestive heart failure and complex ventricular arrhythmias.Clin Pharmacokin 1988;14:187–188.

    Google Scholar 

  56. Mikus G, Gross A, Beckmann J, et al. The influence of the sparteine/debrisoquine phenotype on the disposition of flecainide.Clin Pharmacol Ther 1989;45:562–567.

    PubMed  Google Scholar 

  57. Bennet W. Guide to drug dosage in renal failure. In:Clinical Pharmacokinetics Drug Data Handbook 1989.

  58. Thompson K, Ianasmith D, Siddoway L, et al. Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje Fibers.J Pharmacol Exp Ther 1988;244:950–955.

    PubMed  Google Scholar 

  59. Siddoway L, Thompson K, McAllister B, et al. Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences.Circulation 1987;75:785–791.

    PubMed  Google Scholar 

  60. Kroemer H, Mikus G, Kronbach T, et al. In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone.Clin Pharmacol Ther 1989;45:28–33.

    PubMed  Google Scholar 

  61. McLeod A, Stiles G, Shand D. Demonstration of beta-adrenoceptor blockade by propafenone hydrochloride: clinical pharmacologic, radioligand binding and adenylatecyclase activation studies.J Pharmacol Exp Ther 1984;228:461–466.

    PubMed  Google Scholar 

  62. Lee J, Kroemer H, Silberstein D, et al. The role of genetcally determined polymorphic drug metabolism in the beta-blockade produced by propafenone.N Engl J Med 1990;322:1764–1768.

    PubMed  Google Scholar 

  63. von Philipsborn G, Gries J, Hofmann H, et al. Pharmacological studies on propafenone and its main metabolite 5-hydroxypropafenone.Arzneimittelforsch 1984;34:1489.

    PubMed  Google Scholar 

  64. Otton S, Inaba T, Kalow W. Competitive inhibition of sparteine oxidation in human liver by beta-adrenoceptor antagonists and other cardiovascular drugs.Life Sci 1984;34:73–80.

    Article  PubMed  Google Scholar 

  65. Inaba T, Nakano M, Otton S, et al. A human cytochrome P450 characterized by inhibition studies of the sparteinedebrisoquine monooxygenase.Can J Physiol Pharmacol 1985;62:860–862.

    Google Scholar 

  66. Speirs C et al. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.Br J Clin Pharmacol 1986;22:739–743.

    PubMed  Google Scholar 

  67. Otton S et al. Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome p450 in metoprolol oxidation by human liver microsomes.J Pharmacol Exp Ther 1988;242–247.

  68. Zhou H, Anthony L, Roden D, et al. Quinidine reduces clearance of (+)-propranolol more than (−)-propranolol through marked reduction in 4-hydroxylation.Clin Pharmacol Ther 1990;47:686–693.

    PubMed  Google Scholar 

  69. Funck-Brentano C, Turgeon J, Woosley R, et al. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influences of genetic polymorphism.J Pharmacol Exp Ther 1989;243:134–142.

    Google Scholar 

  70. Hori R, Okumura K, Inui K, et al. Quinidine-induced rise in ajmaline plasma concentration.J Pharm Pharmacol 1984;36:202–204.

    PubMed  Google Scholar 

  71. Zekorn C, Achtert G, Hausleiter H, et al. Pharmacokinetics of N-propylajmaline in relation to polymorphic sparteine oxidation.Klin Wochenschr 1985;63;1180–1186.

    PubMed  Google Scholar 

  72. Schwartzkopff B, Schilling G, Simon H. Comparison of tocainide and prajmalium bitartrate for the treatment of ventricular arrhythmias.Arzneimittel Forsch Drug Res 1988;33:153–158.

    Google Scholar 

  73. Blomgren S, Condemi J, Bignall M, et al. Antinuclear antibody induced by procainamide. A prospective study.N Engl J Med 1969;281:64–66.

    PubMed  Google Scholar 

  74. Kosowsky B, Taylor J, Lown B, et al. Long-term use of procaine amide following acute myocardial infarction.Circulation 1973;47;1204–1210.

    PubMed  Google Scholar 

  75. Woosley R, Drayer D, Reidenberg M, et al. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome.N Engl J Med 1978;298:1157–1159.

    PubMed  Google Scholar 

  76. Henningsen N, Cederberg A, Hanson A, et al. Effects of long term treatment with procaine amide.Acta Med Scand 1975;198:475–482.

    PubMed  Google Scholar 

  77. Drayer D, Reidenberg M. Clinical consequences of polymorphic acetylation of basic drugs.Clin Pharmacol Ther 1977;22:251–258.

    PubMed  Google Scholar 

  78. Lertora J, Arthur J, Atkinson J, et al. Long-term antiarrhythmic therapy with N-acetylprocainamide.Clin Pharmacol Ther 1979;25;273–282.

    PubMed  Google Scholar 

  79. Cooper R, Evans D, Whibley E. Polymorphic hydroxylation of perhexiline maleate in man.J Med Genet 1984;21;27–33.

    PubMed  Google Scholar 

  80. Shah R, Oates N, Idle J, et al. Impaired oxidation of debrisoquine in patients with perhexiline neuropathy.Br Med J 1982;284;295–299.

    Google Scholar 

  81. Shah R, Oates N, Idle J, et al. Prediction of subclinical perhexiline neuropathy in a patient with inborn error of debrisoquine hydroxylation.Am Heart J 1983;105:159–161.

    Article  PubMed  Google Scholar 

  82. Challenor V, Waller D, Renwick A, et al. The transhepatic extraction of nifedipine.Br J Clin Pharmacol 1987;24:473–477.

    PubMed  Google Scholar 

  83. Schellens J, Soons P, Breimer D. Lack of bimodality in nifedipine plasma kinetics in a large population of healthy subjects.Biochem Pharmacol 1988;37:2507–2510.

    Article  PubMed  Google Scholar 

  84. Lobo J, Jack D, Kendall M, et al. The intra- and intersubject variability of nifedipine pharmacokinetics in young volunteers.Eur J Clin Pharmacol 1986;30:57–60.

    Article  PubMed  Google Scholar 

  85. Hoyo-Vadillo, et al. Pharmacokinetics of nifedipine slow release tablet in Mexican subjects; further evidence for an oxidation polymorphism.J Clin Pharmacol 1989;29;816–820.

    PubMed  Google Scholar 

  86. Clark D, Edwards R. Adverse drug reaction reporting and retrospective phenotyping for oxidation polymorphism.Med Toxicol 1988;3:241–247.

    Google Scholar 

  87. Alarcon-Segovia D. Drug-induced lupus syndromes.Mayo Clin Proc 1969;44:664–681.

    PubMed  Google Scholar 

  88. Perry H, Tan E, Carmody S, et al. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine.J Lab Clin Med 1970;76;114.

    PubMed  Google Scholar 

  89. Mansilla-Tinoco R, Harland S, Ryan P, et al. Hydralazine, antinuclear antibodies, and the lupus syndrome.Br Med J 1982;284:936.

    Google Scholar 

  90. Batchelor J, Welsh K, Mansilla-Tinoco R, et al. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility.Lancet 1980;1:1107.

    Article  PubMed  Google Scholar 

  91. Strandberg I, Boman G, Hassler L, et al. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.Acta Med Scand 1976;200;367–372.

    PubMed  Google Scholar 

  92. Heim M, Meyer UA. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplication.Lancet 1990;336:529–532.

    Article  PubMed  Google Scholar 

  93. Turgeon J, Fiscet C, Giguere R, et al. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.J Pharmacol Exp Ther 1991;259;789–798.

    PubMed  Google Scholar 

  94. Beckman J, Hertrampf R, Gundert-Remy U, et al. Is there a genetic factor in flecainide toxicity?Br Med J 1988;297:1316.

    Google Scholar 

  95. Evans D, Mahgoub A, Sloan T, et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.J Met Genet 1980;17:102–105.

    Google Scholar 

Download references

Author information

Affiliations

  1. Division of Clinical Pharmacology and Experimental Therapeutics, San Francisco General Hospital Medical Center, and the University of California, San Francisco, CA, USA

    Neal L. Benowitz M.D.

  2. Kaplan Hospital, 76100, Rehovot, Israel

    Lidia Arcavi

Authors
  1. Lidia Arcavi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neal L. Benowitz M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Arcavi, L., Benowitz, N.L. Clinical significance of genetic influences on cardiovascular drug metabolism. Cardiovasc Drug Ther 7, 311–324 (1993). https://doi.org/10.1007/BF00880154

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00880154

Key Words

  • pharmacogenetics
  • genetic polymorphism
  • acetylation polymorphism
  • debrisoquine/sparteine polymorphism
  • P-450
  • cardiovascular
  • drug metabolism